ANGIOTENSIN-CONVERTING-ENZYME INHIBITOR (ACEI): EFFECTIVE TREATMENT FOR MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (MPGN)?

被引：0
|
作者：
Laube, G. F. [1 ]
Neuhaus, T. J. [1 ]
Nef, S. [1 ]
Sparta, G. [1 ]
机构：
[1] Univ Childrens Hosp, Nephrol Unit, Zurich, Switzerland
来源：
PEDIATRIC NEPHROLOGY | 2009年 / 24卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：1830 / 1830
页数：1
相关论文
共 50 条
  • [31] Treatment of post-transplant erythrocytosis (PTE) with angiotensin-converting enzyme inhibitor (ACEi).
    Pabico, RC
    McKenna, BA
    Yoo, K
    O'Mara, R
    Byer, B
    Yarger, J
    Kremer, M
    Monaghan, J
    Erturk, E
    Orloff, M
    Bonsther, O
    AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (04) : 125A - 125A
  • [32] ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS AND TREATMENT OF HEART-FAILURE
    BRITTON, KE
    GRANOWSKA, M
    PETROSINA, I
    ANAKWENZE, J
    HORNE, T
    LANCET, 1985, 2 (8466): : 1236 - 1236
  • [33] Intravenous Immunoglobulin (IVIG) in the Treatment of Membranoproliferative Glomerulonephritis (MPGN). 1663
    Valerie L. Johnson
    Eduardo M. Perelstein
    David J. Valacer
    Ann E. Stitzel
    Roger E. Spitzer
    Pediatric Research, 1997, 41 (Suppl 4) : 280 - 280
  • [34] Combined angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) therapy is safe and effective in kidney transplant patients
    Reilly, James B.
    Goral, Simin
    Bloom, Roy D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 533 - 533
  • [35] Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: What should be first?
    Remme, Willem J.
    CARDIOLOGY CLINICS, 2007, 25 (04) : 581 - +
  • [36] Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
    Maschio, G
    Alberti, D
    Janin, G
    Locatelli, F
    Mann, JFE
    Motolese, M
    Ponticelli, C
    Ritz, E
    Zucchelli, P
    Marai, P
    Marcelli, D
    Tentori, F
    Andriani, M
    Drago, G
    Meneghel, G
    Oldrizzi, L
    Rugiu, C
    Salvadeo, A
    Villa, G
    Picardi, L
    Borghi, M
    Moriggi, M
    Vendramin, G
    Fusaroli, M
    Esposti, ED
    Fabbri, A
    Koch, KM
    Frey, U
    Schaeffer, J
    Mann, J
    Schweitzer, C
    Zuccala, A
    Gaggi, R
    Stahl, R
    Blaser, C
    Rivolta, E
    Buccianti, G
    Gastaldi, L
    Baratelli, M
    Ducret, F
    Pointet, P
    Sterzel, R
    Oberdorf, E
    Pedrini, L
    Faranna, P
    Cairo, G
    Ferrari, L
    Albertazzi, A
    Cappelli, P
    Cantu, P
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (15): : 939 - 945
  • [37] REVERSIBLE LEUCOPENIA ASSOCIATED WITH ANGIOTENSIN-CONVERTING-ENZYME INHIBITOR MK-421
    STUDER, A
    VETTER, W
    LANCET, 1982, 1 (8269): : 458 - 458
  • [38] EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR (ACEI) IN PATIENTS WITH HEPATITIS-B VIRUS (HBV) AND GLOMERULONEPHRITIS (GN)
    IHM, CG
    CHEONG, HJ
    KO, KS
    AHN, JH
    LEE, TW
    KIM, MJ
    KIDNEY INTERNATIONAL, 1993, 44 (05) : 1184 - 1184
  • [39] COUGH INDUCED BY ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS
    RUMORE, MM
    RUMORE, JS
    CLINICAL PHARMACY, 1989, 8 (01): : 11 - 12
  • [40] Promoting use of angiotensin-converting-enzyme inhibitors
    CookeAriel, H
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (03) : 264 - 264
12345